Related by context. All words. (Click for frequent words.) 69 lymphadenectomy 69 SLNB 68 sentinel node biopsy 68 sentinel lymph node biopsy 67 axillary dissection 67 radical nephrectomy 66 pCR 66 FDG-PET/CT 66 urine cytology 66 F FDG PET 66 EUS FNA 65 core needle biopsies 65 multivariable analysis 65 nephrectomy 65 axillary node dissection 65 scintigraphic 65 immunohistochemical analysis 65 transvaginal sonography 65 lymph node dissection 65 pelvic lymphadenectomy 64 neoadjuvant chemotherapy 64 #F FDG PET 64 Kaplan Meier analysis 64 postoperative chemotherapy 64 immunohistochemical 64 thyroglobulin 64 sentinel node 64 EBUS FNA 64 neoadjuvant therapy 64 univariate 64 adjuvant radiotherapy 64 multivariate analyzes 64 micrometastasis 64 multivariate Cox 64 ultrasonographic 64 transabdominal 63 operable breast cancer 63 nodal dissection 63 hepatectomy 63 debulking surgery 63 histopathologic examination 63 excisional biopsy 63 nodal metastases 63 breast carcinoma 63 axillary lymph nodes 63 conventional angiography 63 cystectomy 63 postoperative radiotherapy 63 axillary lymph node dissection 63 chemoradiotherapy 63 mammographic density 63 histopathologic 62 TRUS 62 cytologic 62 adrenalectomy 62 chest radiographs 62 elective PCI 62 preoperative diagnosis 62 postoperative complication 62 radical cystectomy 62 node dissection 62 thyroidectomy 62 FDG PET 62 immunohistochemical staining 62 laparoscopic cholecystectomy 62 fine needle aspiration 62 adjuvant radiation 62 axillary nodes 62 endometrial carcinoma 62 neoadjuvant treatment 62 PSA nadir 62 pT2 62 cytoreductive surgery 62 preoperative chemotherapy 62 mucinous 62 pelvic ultrasound 62 pelvic lymph node dissection 62 urothelial carcinoma 62 allogeneic transplant 62 randomized controlled trials RCTs 62 sonographic findings 62 core needle biopsy 62 salpingo oophorectomy 62 epithelial ovarian cancer 61 endometrial biopsy 61 FDG PET CT 61 TURBT 61 locoregional recurrence 61 ERCP 61 prostate biopsy 61 sonographically guided 61 preoperative staging 61 prostate cancer CaP 61 transurethral resection 61 chemoradiation therapy 61 lymphocytosis 61 serum PSA 61 cytological 61 pancreatic adenocarcinoma 61 ASCUS 61 logistic regression models 61 Radical prostatectomy 61 adjuvant therapy 61 histologic examination 61 undetectable HBV DNA 61 chemoembolization 61 karyotyping 61 meniscectomy 61 radical retropubic prostatectomy 61 TRUS biopsy 61 axillary lymph node 61 ALND 61 VATS lobectomy 61 cardiac perfusion 61 neoadjuvant 61 Immunohistochemistry 61 abdominal hysterectomy 61 postintervention 61 conditional logistic regression 61 curative resection 61 NMIBC 61 radioiodine therapy 61 logistic regression analyzes 61 hip resurfacing arthroplasty 61 upper endoscopy 61 Histologic 60 bone scintigraphy 60 chemoradiation 60 subgroup analyzes 60 OvaRex MAb 60 oncologic outcomes 60 invasive ductal 60 immunostaining 60 total thyroidectomy 60 sonographic evaluation 60 prostate carcinoma 60 liver resection 60 liver biopsies 60 Response Evaluation Criteria 60 clinicopathological 60 biochemical relapse 60 intraobserver 60 adnexal mass 60 adenoma recurrence 60 arteriography 60 renal cell carcinomas 60 SUVmax 60 sentinel lymph nodes 60 transrectal ultrasound guided 60 sentinel nodes 60 urodynamic 60 pathologic examination 60 preoperative MRI 60 lymph node involvement 60 CIN2 + 60 liver metastasis 60 atypical hyperplasia 60 PET CT scans 60 postoperative mortality 60 estrogen receptor ER 60 Kaplan Meier method 60 HGPIN 60 clinicopathological features 60 plain radiographs 60 T1a 60 renal tumors 60 lymphovascular invasion 60 liver biopsy 60 biochemical recurrence 60 multiple logistic regression 60 D dimer 60 transthoracic 60 interobserver 60 vaginal hysterectomy 60 lymph node metastasis 60 Poisson regression 60 distant metastasis 60 myocardial viability 60 cranial irradiation 60 cytoreductive nephrectomy 60 Logistic regression 60 etiologic 60 BRCA mutation carriers 60 CIN3 60 transesophageal echocardiography 60 underwent surgical resection 60 pneumonectomy 60 myocardial revascularization 60 duplex ultrasonography 60 HER2 expression 60 Doxil ® 60 FDG PET imaging 60 Bonferroni correction 59 histological subtype 59 surgical biopsies 59 logistic regression analysis 59 5-fluorouracil/leucovorin 59 advanced neoplasia 59 lymph node metastases 59 sonographic examination 59 advanced adenomas 59 Kruskal Wallis test 59 Lymph node 59 mediastinoscopy 59 ABVD 59 ultrasound elastography 59 univariate analyzes 59 coronary arteriography 59 contralateral breast 59 histologically proven 59 metaplasia 59 OPCAB 59 Multivariate logistic regression 59 radiotherapy RT 59 sentinel lymph node 59 locoregional 59 genotypic resistance 59 progesterone receptor PR 59 cytologic examination 59 Randomized clinical trials 59 hepatic resection 59 colonography 59 hamartomas 59 cTnI 59 univariate analysis 59 tumor excision 59 oophorectomy 59 gadolinium enhanced 59 HER2 overexpression 59 posttreatment 59 segmentectomy 59 PLCO trial 59 ARB telmisartan 59 peritoneal carcinomatosis 59 peritoneal cancer 59 invasive carcinomas 59 eptifibatide 59 clinico pathological 59 intraperitoneal chemotherapy 59 HoLEP 59 axillary node 59 meta analytic 59 coronary CTA 59 HER2 amplification 59 intravesical therapy 59 thyroid nodules 59 nodal metastasis 59 MR spectroscopy 59 Subgroup analysis 59 lung resection 59 leiomyomas 59 remission CR 59 endoscopic ultrasound 59 LAGB 59 biopsied tissue 59 nomograms 59 BRCA2 mutation carriers 59 R0 resection 59 GnRH agonists 59 multivariate logistic regression 59 micrometastases 59 transrectal ultrasound 59 pretest probability 59 androgen deprivation 59 histopathological 59 EBRT 59 Doppler sonography 59 retrospective cohort 59 urinary cytology 59 histologic subtype 59 response pCR 59 TACE 59 needle aspiration 59 rFSH 58 tamoxifen therapy 58 VCUG 58 partial nephrectomy 58 resections 58 carotid stenosis 58 Oncotype DX Recurrence Score 58 cerebral angiography 58 BCIRG 58 colorectal adenoma 58 lymph node removal 58 K ras mutations 58 microsatellite instability 58 XELOX 58 colonoscopic 58 sensitivity specificity 58 perioperative mortality 58 preoperative PSA 58 endometrial thickness 58 cytoreduction 58 HBsAg 58 lobular carcinoma 58 multivariate regression analysis 58 Pearson correlation coefficients 58 underwent resection 58 gastrectomy 58 conventional cytology 58 pT3 58 angiographically 58 RECIST Response Evaluation Criteria 58 invasive carcinoma 58 immunohistochemistry IHC 58 malignant lesions 58 cervical carcinoma 58 carotid IMT 58 endometrial adenocarcinoma 58 ductal carcinomas 58 conventional coronary angiography 58 sonographically 58 perioperative morbidity 58 aneuploidy screening 58 renal biopsy 58 bilateral oophorectomy 58 histologic 58 KRAS mutation 58 adjuvant systemic 58 venography 58 chi squared 58 interrater reliability 58 sonographic 58 clinically localized prostate 58 esophagectomy 58 computed tomographic 58 robotic radical prostatectomy 58 nephron sparing surgery 58 SYNTAX trial 58 logistic regression 58 invasive lobular carcinoma 58 colorectal liver metastases 58 sleeve lobectomy 58 NSABP B 58 RT qPCR 58 Angiogram 58 HCV SPRINT 58 FDG uptake 58 Cystectomy 58 retroperitoneal 58 Subgroup analyzes 58 mutated K ras 58 histopathologic diagnosis 58 prostatic adenocarcinoma 58 endosonography 58 HRCT 58 revascularizations 58 prospectively randomized 58 invasive coronary angiography 58 histopathological examination 58 contralateral breast cancer 58 distant metastases 58 Angiographic 58 PSADT 58 antiangiogenic therapy 58 definite stent thrombosis 58 haematological 58 coronary stenosis 58 tumor biopsies 58 preoperative radiotherapy 58 LV dysfunction 58 incomplete revascularization 58 prognostic significance 58 PITX2 58 nomogram 58 #F FDG 58 beam radiotherapy 58 imatinib therapy 58 chest radiography 58 wedge resection 58 metastatic lesion 57 ICD implantation 57 transient elastography 57 orchiectomy 57 BRAF V#E mutation 57 CR nPR 57 pathologic diagnosis 57 transvaginal ultrasound 57 ER CHOP 57 resectable 57 external beam radiotherapy 57 androgen suppression 57 EBUS 57 posttest 57 metastatic RCC 57 endometrial biopsies 57 ultrasonography 57 #Gy 57 preoperative evaluation 57 glomerular filtration 57 meta regression 57 Reynolds Risk Score 57 NSTE ACS 57 prognostic variables 57 interobserver reliability 57 adenoma 57 multivariable Cox 57 adenoma detection 57 Adjuvant chemotherapy 57 NMP# 57 beta blocker therapy 57 Immunohistochemical staining 57 cholecystectomy 57 gemcitabine Gemzar 57 radical prostatectomy RP 57 BEXXAR Therapeutic Regimen 57 Digital Mammographic Imaging 57 RARP 57 histological diagnosis 57 undergone radical prostatectomy 57 malignant polyps 57 endoscopic retrograde 57 HSCT 57 Cardiopulmonary bypass 57 logistic regression model 57 multivariable logistic regression 57 fallopian tube cancers 57 semiquantitative 57 Adjuvant therapy 57 CRp 57 surgical debulking 57 Zevalin consolidation 57 percutaneous biopsy 57 HER2 negative 57 MDRD 57 surgically resectable 57 para aortic 57 cystoscopic 57 adenomatous polyps 57 polyp detection 57 taxane therapy 57 histologic diagnosis 57 mg BID dose 57 adjuvant chemotherapy 57 seminoma 57 parenteral antibiotics 57 CT coronary angiography 57 ASCT 57 Accelerated Partial Breast Irradiation 57 resected pancreatic cancer 57 transcranial Doppler ultrasound 57 node metastases 57 cytogenetic abnormalities 57 colorectal adenocarcinoma 57 hepatic metastases 57 mycophenolate mofetil 57 qRT PCR 57 lobular carcinomas 57 endoscopic resection 57 tumorigenicity 57 DXA scan 57 thymoma 57 undergoing coronary angiography 57 surgical biopsy 57 TNM staging 57 Surgical resection 57 Bonferroni 57 trabeculectomy 57 MGd 57 nucleotide substitutions 57 follicular thyroid cancer 57 MTT assay 57 intima media thickness 57 aromatase inhibitor therapy 57 postoperative radiographs 57 seropositivity 57 hydronephrosis 57 coronary angiography 57 β blockers 57 MammaPrint R 57 sonographic examinations 57 sDNA 57 endocrine therapy 57 paclitaxel eluting stents 57 Ultrasonography 57 transthoracic echocardiography 57 myocardial necrosis 57 lung nodule 57 intraoperative complications 57 Sentinel Lymph Node Biopsy 57 tumor resection 57 adnexal masses 57 TOP2A 57 catheter angiography 57 color Doppler sonography 57 logistic regressions 57 situ LCIS 57 thoracoscopic lobectomy 57 Recurrence Score 57 PLCO 57 breast cancer subtypes 57 biopsy Gleason 56 DEXA scans 56 FDG PET scans 56 binary logistic regression 56 antibody titer 56 diagnostic angiography 56 gauge vitrectomy 56 leiomyoma 56 endoscopic examinations 56 guaiac 56 liver transplant recipients 56 DEXA scan 56 advanced adenoma 56 metachronous 56 troponin T 56 trastuzumab Herceptin ® 56 embolizations 56 helical CT 56 atherosclerotic renal artery stenosis 56 troponins 56 endometrioid 56 mammographically 56 HCV RESPOND 2 56 revascularization procedure 56 inotropic 56 folate supplementation 56 proteomic analysis 56 choriocarcinoma 56 HNSCC 56 acetabular fracture 56 urine dipstick 56 adenoidectomy 56 dobutamine stress 56 ERBB2 56 prognostic indicator 56 fluorodeoxyglucose positron emission tomography 56 laparoscopic radical nephrectomy 56 adjuvant trastuzumab 56 prospectively defined 56 transcranial Doppler 56 Fontan procedure 56 bladder carcinoma 56 histological examination 56 intact parathyroid hormone 56 noninvasive imaging 56 transrectal 56 resected 56 cisplatin resistant 56 histopathology 56 serum estradiol 56 TURP 56 electron beam computed tomography 56 chlamydial infection 56 adjuvant hormonal therapy 56 Estrogen Receptor 56 mediastinal 56 Histopathologic 56 recurrent glioblastoma multiforme 56 nonmetastatic 56 serologic testing 56 echocardiographic 56 OGTT 56 carboplatin paclitaxel 56 convergent validity 56 papillary thyroid carcinoma 56 thyroid carcinoma 56 baseline LDH 56 adjuvant therapies 56 revascularization procedures 56 CT angiogram 56 Cystoscopy 56 optical colonoscopy 56 patients undergoing CABG 56 Mantel Haenszel 56 carcinoembryonic antigen 56 prospective longitudinal 56 histopathologic findings 56 Papillary 56 serrated polyps 56 cervical cytology 56 RECIST criteria 56 needle biopsy 56 visceral metastases 56 methotrexate therapy 56 cerebral angiogram 56 inhibin 56 TEVAR 56 intravascular ultrasonography 56 Preoperative 56 postoperative morbidity 56 iodixanol 56 hormone receptor status 56 transvaginal 56 recurrent metastatic 56 ovarian malignancy 56 maternal serum 56 NSABP 56 concurrent chemoradiation 56 metaanalysis 56 Multivariate analysis 56 PCI ExTRACT TIMI 56 gastric adenocarcinoma 56 microdose 56 variance ANOVA 56 CsA 56 platelet reactivity 56 pegylated liposomal doxorubicin 56 apolipoproteins 56 STRIDE PD 56 TIMP 56 lung biopsy 56 adjuvant tamoxifen 56 familial aggregation 56 Linear regression 56 asymptomatic carotid stenosis 56 Histopathological 56 thymectomy 56 intestinal metaplasia 56 GISTs 56 IL#B 56 tumor histology 56 Ebstein anomaly 56 parathyroidectomy 56 morphologic 56 malignant growths 56 cardiac troponin 56 euthyroid 56 Multiple logistic regression 56 PSA kinetics 56 nephrectomies 56 hepatocellular carcinomas 56 CCyR 56 cytotoxic therapy 56 sonographic diagnosis 56 morphometric vertebral fractures 56 recurrent GBM 56 Tumor Response 56 perfusion CT 56 PCWP 56 mediastinal lymph nodes 56 mg kg dose 56 randomized multicenter trial 56 subanalysis 56 covariate 56 hyperinsulinemic euglycemic clamp 56 Xelox 56 Coronary Artery Bypass Graft 56 stratifying patients 56 clinicopathologic 56 dosimetric 56 sternotomy 56 antigen PSA 56 cystoscopy 56 MDRD equation 56 Histological 56 adenotonsillectomy 56 pulmonary angiography 56 prospective multicenter study 56 prostate biopsies 55 Common Toxicity Criteria 55 cardiac computed tomography 55 tissue biopsies 55 DSM IV diagnoses 55 busulfan 55 intestinal biopsy 55 colectomy 55 NIHSS score 55 risk reducing salpingo 55 nonmelanoma skin cancers 55 tumoral 55 pretargeting 55 coronary revascularization 55 diagnostic modality 55 nonrandomized studies 55 colon capsule endoscopy 55 periprosthetic infection 55 transrectal ultrasonography 55 papillary carcinoma 55 hematopoietic cancers 55 X ray angiography 55 radionuclide imaging 55 extracolonic findings 55 Univariate 55 radial artery grafts 55 MGUS 55 serum biomarkers 55 prostate cancer PCa 55 mCi 55 Randomized trials 55 #.#ng/ml 55 atypical ductal hyperplasia 55 FOLFOX4 55 periprocedural 55 total abdominal hysterectomy 55 clopidogrel pretreatment 55 localized renal 55 dimensional echocardiography 55 renal carcinoma 55 virological response 55 underwent radical prostatectomy 55 retrospective cohort study 55 autologous SCT 55 MDCT angiography 55 aneuploidy 55 HOMA IR 55 colorectal carcinoma 55 eNO 55 echocardiographic parameters 55 BRCA1 mutation carriers 55 Circulating tumor cells 55 pairwise comparisons 55 DXA 55 cytogenetic response 55 malignant nodules 55 Neoadjuvant 55 multimodality therapy 55 vascular lesion 55 biopsies 55 lipid lowering therapy 55 liver metastases 55 estimated glomerular filtration 55 quantitative RT PCR 55 Aspergillus nidulans 55 PCPT 55 esophagogastroduodenoscopy 55 RALP 55 low expressors 55 cardiac troponin T 55 MTWA testing 55 Chemoradiation 55 transcriptional profiling 55 prospective nonrandomized 55 FGFR2 gene 55 surgical excision 55 ABSORB trial 55 standard chemotherapy regimen 55 sCJD 55 sirolimus eluting stents 55 multivariate analysis 55 Bezielle 55 endoscopic retrograde cholangiopancreatography ERCGrant Parpan 55 perfusion abnormalities 55 NNRTI resistance 55 factorial design 55 CC genotype 55 dimensional sonography 55 metastatic lymph nodes 55 specific antigen PSA 55 TKAs 55 Postoperative complications 55 epidural steroid injections 55 radiofrequency catheter ablation 55 CT angiography 55 ImmuKnow assay 55 appendiceal 55 STEP BD 55 medically inoperable 55 mammographic 55 pars plana vitrectomy 55 relapsed MM 55 transarterial chemoembolization 55 renal transplantation 55 radiographic examinations 55 percutaneous vertebroplasty 55 intraventricular 55 Computed tomography 55 seminal vesicle invasion 55 eGFR 55 extracapsular extension 55 prior nephrectomy 55 metastatic malignant melanoma 55 laparotomy 55 stage IIIB 55 Hurthle cell 55 atypia 55 rFVIIa 55 TIMP 1 55 KRAS status 55 Squamous 55 NCCTG N# 55 differential gene expression 55 preimplantation genetic screening 55 Hilakivi Clarke 55 breast carcinomas 55 histologically confirmed 55 genomewide 55 denervation 55 sustained virological response 55 galiximab 55 Sentinel lymph node 55 papillary renal cell carcinoma 55 ProstaScint 55 oral Xeloda 55 endometrial cancers 55 prognostic factors 55 viral kinetics 55 chemotherapy docetaxel 55 Coronary angiography 55 posttransplant 55 singleton pregnancies 55 unfractionated heparin UFH 55 prophylactic cranial irradiation 55 benign nodules 55 artery embolization 55 ischemic lesions 55 Abdominal ultrasound 55 CT Colonography 55 prognostic biomarker 55 Likert scale 55 multivessel disease 55 pegylated interferon alfa 2b 55 nonobstructive CAD 55 CEUS 55 transfemoral approach 55 PET CT scan 55 nonoperative 55 OncotypeDX 55 RT PCR assay 55 invasive diagnostic 55 prognostic indicators 55 metastatic malignant 55 radiographic findings 55 Zemiva imaging 55 lymphocyte count 55 contralateral 55 ELISpot 55 Eur Urol 55 contrast echocardiography 55 BRCA testing 55 recanalization 55 FDG PET scan 55 ErbB2 positive 55 serum thyroglobulin 55 spirometric 55 DCE MRI 55 pancreatic resection 55 ANOVA 55 Immunohistochemical analysis 55 dose dexamethasone 55 Fractional Flow Reserve 55 biliary tract cancer 55 induced sputum 55 spiral computed tomography 55 malignant neoplasms 55 retrospective observational study 55 KRAS wild 55 percutaneous drainage 55 benign lesions 55 Ductal carcinoma 55 pretransplant 55 coronary angiogram 55 EDEMA3 trial 55 recurrent miscarriage 55 Biopsies 55 PCa 55 Sentinel node biopsy 55 Burch colposuspension 55 nerve sparing 55 BERKELEY CA UroToday.com 55 MAGE A3 ASCI 55 PITX2 methylation 55 Stenting Trial CREST 55 prophylactic oophorectomy 55 CHADS2 55 MMSE score 55 perfusion imaging 55 symptomatic VTE 55 colorectal neoplasms 55 epithelial tumors 55 colon rectal 55 scintigraphy 55 antitumor effect 55 periprocedural MI 55 Echocardiographic 55 colon resection 55 BRAF mutation 55 immunohistochemistry 55 radiochemotherapy 55 thromboprophylaxis 55 randomizing patients 55 PROLARIS 55 extrapleural pneumonectomy 55 precursor lesions 55 KRAS mutations occur 55 knee arthroplasty 55 carotid intima media 55 contralateral prophylactic mastectomy 55 promoter methylation 54 ExTRACT TIMI 54 CALGB 54 Coronary CTA 54 hMG 54 preoperatively 54 postmenopausal hormone 54 cervical lesions 54 estimated GFR 54 computed tomography scans 54 florbetaben 54 biventricular repair 54 arthrography 54 SABCS 54 bivariate 54 T1 weighted images 54 virologic failure 54 abdominal ultrasounds 54 bronchogenic carcinoma 54 gemcitabine carboplatin 54 EORTC 54 hematuria 54 Cytogenetic 54 bioluminescence imaging 54 Pearson correlation coefficient 54 axilla 54 oral anticoagulation 54 CTEPH 54 enhanced sonography 54 sarcomatoid 54 histologically 54 antiplatelet therapy 54 BARI 2D 54 Cardiotoxicity 54 fluvastatin 54 Radiographs 54 LV ejection fraction 54 occult metastases 54 PCA3 54 chromosomal aberrations 54 KRAS mutation status 54 BRCA mutations 54 ductal lobular 54 multicenter trials 54 Getzenberg 54 Amniocentesis 54 IIIA NSCLC 54 carotid artery stenosis 54 BI RADS 54 B7 H3 54 COR Analyzer 54 hormone therapy estrogen 54 FOLFOX6 54 ovarian stimulation 54 HLA A2 54 NIHSS 54 IV NSCLC 54 normal karyotype 54 coronary calcification 54 nondiagnostic 54 Screening Trial DMIST 54 explanatory variables 54 haematologic 54 HIPEC 54 selenium supplementation 54 Oncotype 54 ovarian carcinoma 54 arthroplasties 54 Cardiorespiratory fitness 54 adjuvant endocrine therapy 54 trabectedin 54 intra arterial chemotherapy 54 androgen ablation 54 Prostate Specific Antigen PSA 54 phase IIIb 54 polypectomy 54 preintervention 54 cranial radiation 54 somatic mutations 54 urothelial cancer 54 chemotherapeutic regimen 54 fibroma 54 paracentesis 54 methotrexate monotherapy 54 coronary CT angiography 54 enucleation 54 EGFR mutation status 54 abdominal ultrasound 54 dimensional computed tomography 54 MRgFUS 54 neoadjuvant chemoradiotherapy 54 fundoplication 54 angiography CCTA 54 postprocedure 54 CHAMPION PCI 54 goserelin 54 noninvasive outpatient 54 BENICAR HCT 54 invasive angiography 54 thyroid stimulating hormone 54 diabetes mellitus DM 54 standard chemotherapy regimens 54 abnormal cytology 54 fluoroscopy guided 54 enhanced MR angiography 54 XIENCE V PROMUS Stent 54 lymphoproliferative disorders 54 stage IIIA 54 endorectal coil 54 SLNs 54 intralesional 54 methylation markers 54 QTc prolongation 54 esophageal carcinoma 54 Prostate specific antigen 54 squamous 54 precancerous polyp 54 HIV HCV coinfected 54 allogeneic SCT 54 heavily pretreated patients 54 FFR guided